Christopher Wicher, MD
Urology · Missoula, MTNPI 1770779225
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,007 of the $2,236 with a category attached, or 89.8%. It is spread thinly across 30 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations.
Across 104 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$319
- Astellas Pharma US Inc$292
- Johnson & Johnson$251
- Pfizer$212
- Dendreon Pharmaceuticals LLC$153
- Intuitive Surgical$150
- plus $860 from 24 others
What the payments were for
- Speaking & faculty fees$1507%
- Food & beverage$2,00790%
- Education$794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $319 |
| Astellas Pharma US Inc | 11 | $292 |
| Johnson & Johnson | 11 | $251 |
| Pfizer | 13 | $212 |
| Dendreon Pharmaceuticals LLC | 6 | $153 |
| Intuitive Surgical | 1 | $150 |
| Rochester Medical Corporation | 7 | $134 |
| Axonics, Inc. | 3 | $110 |
| Bayer | 1 | $57 |
| Boston Scientific | 2 | $55 |
| Ambu Inc. | 3 | $53 |
| 180 Medical, Inc. | 2 | $48 |
| Myovant Sciences Inc. | 2 | $39 |
| Urogen Pharma, Inc. | 2 | $37 |
| Laborie Medical Technologies Corp. | 2 | $37 |
| Teleflex LLC | 2 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $34 |
| Coloplast | 2 | $32 |
| Myriad Genetic Laboratories, Inc. | 2 | $23 |
| Novartis | 1 | $19 |
| Immunitybio, Inc. | 1 | $18 |
| Dornier Medtech America, Inc | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Telix Pharmaceuticals | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Calyxo, Inc. | 1 | $15 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Procept Biorobotics Corporation | 1 | $14 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$150
How this compares
$2,236 in reported general payments places this provider in the 55th percentile of 45 urology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 44 | $615,163 |
| ErleadaApalutamide | 12 | $174,677 |
| Abiraterone Acetate | 79 | $90,625 |
| OrgovyxRelugolix | 21 | $54,951 |
| MyrbetriqMirabegron | 42 | $27,375 |
| Tamsulosin Hcl | 351 | $5,395 |
| Finasteride | 174 | $2,399 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,595 |
| Methenamine Hippurate | 17 | $1,059 |
| Oxybutynin Chloride ErOxybutynin Chloride | 58 | $787 |
| Testosterone Cypionate | 16 | $676 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $452 |
| Prednisone | 56 | $441 |
| Ciprofloxacin Hcl | 19 | $227 |
| Tramadol Hcl | 125 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $292 | $642,53886 claims |
| Johnson & JohnsonErleada | $251 | $174,67712 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $16 | $54,95121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 45 urology providers in Montana.
Other urology in Missoula
- Garrick SimmonsMissoula$16K
- Jeffrey RedshawMissoula$4K
- Karl WestenfelderMissoula$4K
- Matthew MundingMissoula$3K
- Jason ReynoldsMissoula$2K
- Kevin KronnerMissoula$2K
- Christopher FukudaGreat Falls$19K
- Morris JessopGreat Falls$12K
- Jason SkenazyBozeman$12K
- Amy McKerrowKalispell$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.